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Summary  The  development  of  transcatheter  aortic  valve  implantation  (TAVI)  by  our  group
has  been  a  20-year  odyssey.  In  1993,  postmortem  studies  validated  the  concept  of  intravalvular
stenting in  calciﬁc  aortic  stenosis.  The  ﬁrst  prototypes  of  balloon-expandable  valves  were  tested
in  an  animal  model  in  2000.  The  ﬁrst-in-man  implantation  was  performed  in  Rouen  in  2002,
rapidly  followed  by  two  prospective  series  in  compassionate  cases  in  our  centre.  TAVI  took
ﬂight  in  2004  in  the  hands  of  Edwards  Lifesciences,  with  major  improvements  in  devices  and
approaches.  At  the  same  time,  the  self-expanding  CoreValve  was  launched.  Thousands  of  high-
surgical-risk  patients  were  enrolled  in  feasibility  studies,  leading  to  the  Conformité  Européenne
(CE)  mark  being  granted  in  2007  for  the  two  devices.  A  number  of  postmarketing  registries  have
shown  dramatic  improvements  in  procedural  and  midterm  results  and  decreased  complication
rates,  with  more  experience  and  improved  technology.  The  results  of  the  randomized  PARTNER
study  in  the  USA  recently  conﬁrmed  the  important  place  of  TAVI  in  non-operable  and  high-
surgical-risk  patients.  To  date,  more  than  50,000  patients  have  beneﬁted  from  TAVI  worldwide
(2300  patients  in  33  centres  in  France  in  2011)  and  the  number  is  consistently  increasing.  An
optimal  multidisciplinary  collaboration  and  formally  trained  experienced  physicians  are  the
keys  to  success.  An  extension  of  indications  to  lower-risk  patients  might  be  expected  in  the
coming  years  but  should  be  cautiously  investigated.  Ten  years  after  the  ﬁrst-in-man  case,  TAVI
is  here  to  stay  and  the  future  is  promising.
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Résumé  Le  développement  du  Transcatheter  Aortic  Valve  Implantation  (TAVI)  par  notre
groupe  a  été  une  odyssée  de  20  ans.  En  1993,  une  étude  en  postmortem  a  validé  le  concept
de stenting  intravalvulaire  dans  le  rétrécissement  aortique  calciﬁé.  Les  premiers  prototypes  de
valve  expansible  par  ballonnet  ont  pu  être  testés  sur  l’animal  en  2000.  La  première  implantation
chez  l’homme  a  été  réalisée  à  Rouen  en  2002,  rapidement  suivie  de  deux  études  prospectives
réalisées  par  notre  groupe  dans  des  situations  compassionnelles.  Le  TAVI  a  pris  réellement  son
essor  entre  les  mains  d’Edwards  Lifesciences  avec  des  améliorations  majeures  du  matériel  et
des  approches.  À  la  même  époque  était  lancée  la  valve  autoexpansible  CoreValve.  Des  milliers
de  patients  à  haut  risque  chirurgical  ont  été  enrôlés  dans  des  études  de  faisabilité  aboutis-
sant  au  marquage  Conformité  Européenne  (CE)  pour  les  deux  modèles  de  valve  en  2007.  Un
grand  nombre  de  registres  post-commercialisation  ont  montré  une  amélioration  très  impor-
tante  des  résultats  immédiats  et  à  moyen  terme  et  une  diminution  du  taux  de  complication  liée
à  l’expérience  des  équipes  et  aux  avancées  technologiques.  Les  résultats  de  l’étude  randomisée
PARTNER  aux  États-Unis  ont  récemment  conﬁrmé  la  place  importante  du  TAVI  pour  les  patients
inopérables  ou  à  haut  risque  chirurgical.  Aujourd’hui,  plus  de  50  000  patients  ont  bénéﬁcié  du
TAVI  dans  le  monde  (2300  patients  dans  33  centres  en  France  pour  l’année  2011)  et  le  nombre  ne
cesse  de  croître.  Une  collaboration  multidisciplinaire  et  un  entraînement  optimal  des  équipes
sont  la  clef  du  succès.  Une  extension  des  indications  aux  patients  à  moindre  risque  est  à  prévoir
dans  les  années  qui  viennent,  sous  réserve  d’investigations  contrôlées.  Dix  ans  après  le  premier
cas  mondial,  le  TAVI  est  une  technique  bien  établie  et  dont  le  futur  est  très  prometteur.
© 2012  Elsevier  Masson  SAS.  
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Cet article est publié en Open Access sous licence CC BY-NC-ND.Background
If  the  development  of  transcatheter  aortic  valve  implan-
tation (TAVI)  by  our  group  in  France  can  be  considered  a
‘‘success story’’  today,  it  is  nothing  short  of  a  miracle,  as
the project  appeared  particularly  challenging  —– not  to  say
totally unrealistic  —– at  its  origin  in  the  early  1990s.  It  is  quite
thrilling, therefore,  to  observe  the  current  acceptance  and
expansion of  this  technology  worldwide,  10  years  after  the
‘‘heroic’’ ﬁrst-in-man  TAVI  procedure  performed  in  Rouen
on April  16th,  2002.
We report  here  the  main  phases  of  this  20-year  odyssey
and brieﬂy  consider  future  prospects,  as  TAVI  remains  in  a
process of  continuous  development.
Birth of a concept
The  starting  point  of  this  adventure  took  place  at  the  end
of the  1980s,  with  the  evidence  of  the  limitations  of  bal-
loon aortic  valvuloplasty  (BAV),  a  technique  that  we  had
pioneered since  1985  [1]  for  the  treatment  of  non-operable
calciﬁc aortic  stenosis  (AS).  The  goal  of  BAV  was  to  provide
a therapeutic  option  for  patients  considered  at  that  time  to
be inoperable,  often  because  age  more  than  75  years  per  se
was a  customary  contraindication  to  aortic  valve  replace-
ment (AVR)  in  the  1980s.  BAV  was  associated  with  midterm
improvement in  quality  of  life  [2],  explaining  its  rapid  adop-
tion and  explosive  growth  worldwide.  However,  the  lack  of
survival beneﬁt  and  a  recurrence  rate  of  80%  at  1  year  [3,4]
led to  a  dramatic  decline  in  its  use.
For  us,  addressing  the  issue  of  post-BAV  valvular  resteno-
sis soon  became  an  obsession.  The  idea  of  placing  within
the diseased  valve  a  large-size  stent  containing  a  mounted
i
t
p
arosthesis  (stented  valve)  was  rapidly  considered  an  optimal
otential option.
Actually,  the  concept  of  transcatheter  heart  valve
mplantation was  not  new.  In  the  1970s,  several  projects
imed at  treating  aortic  regurgitation  [5—7]  remained
xperimental. In  1989,  Henning-Rud  Andersen  ﬁrst
mplanted an  original  model  of  a balloon-expandable
atheter-mounted  stented  valve  within  the  aorta  of  pigs,
sing a  handmade  mesh  containing  a  porcine  valve.  The
esults, published  in  1992  [8],  were  not  followed  by
uman application.  Other  experimental  concepts  emerged
hereafter [9—11].  In  2000,  Philip  Bonhoeffer  developed  a
tented valve  made  of  a  bovine  jugular  vein  conduit  inserted
n a  platinum-iridium  stent,  which  was  implanted  in  the
ulmonary artery  of  lambs  [12].  Bonhoeffer  performed  the
rst human  implantation  of  this  device  in  a  right  ventricle
o pulmonary  artery  conduit  in  2000  [13],  followed  by
ntense development  of  the  technology  in  this  indication.
imultaneously, we  speciﬁcally  addressed  degenerative  AS,
 highly  challenging  indication,  regarding  the  speciﬁcity  of
he calciﬁc  aortic  valve  and  surrounding  structures.
irst observations, enthusiasm and
rustration
n  1993  to  1994,  we  demonstrated  in  12  fresh  specimens  of
alciﬁc AS  that  a  Palmaz  stent,  23  mm  in  diameter,  could
ircularly open  each  native  valve,  regardless  of  the  amount
f calciﬁcation.  The  ideal  height  of  the  stent  appeared  to  be
4 to  16  mm  to  avoid  impinging  on  the  coronary  ostia,  the
ntraventricular septum  or  the  anterior  mitral  valve  leaﬂet,
hus duplicating  the  subcoronary  position  of  any  surgical  bio-
rosthesis.  The  stents  were  well  anchored  within  the  aortic
nnulus, requiring  a  high  traction  force  to  be  dislodged,  thus
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imiting  the  risk  of  embolization.  This  study,  which  validated
he concept  of  aortic  valvular  stenting  in  a  model  of  human
alciﬁc AS,  was  a  fundamental  milestone.  However,  at  that
ime, the  type  of  valve  prosthesis  and  its  physical  properties
ere still  at  the  drawing  stage.
Over  a  4-year  period,  the  search  for  a  biomedical
ompany that  was  interested  in  the  project  failed  com-
letely. A  long  list  of  engineering  issues  and  potential
omplications was  consistently  pointed  out,  including  coro-
ary obstruction,  aortic  and  mitral  valve  complication,
arly dislodgement  of  the  device,  stroke,  mechanical
omplications, etc.  The  project  was  even  considered  ‘‘the
ost stupid  ever  heard’’!
ercutaneous valve technologies: the end
f  the tunnel
o  accomplish  this  venture,  a  start-up  company,
‘Percutaneous  Valve  Technologies’’  (PVT,  NJ,  USA)  was
nally formed  in  1999.  Engineers  from  Israel  were  able  to
esign the  ﬁrst  models  of  balloon-expandable  transcatheter
eart valve  (THV),  which  consisted  of  a  stainless  steel  stent
ntegrating a  tri-leaﬂet  polyurethane  valve.  Considerable
aboratory work  was  done  before  obtaining  the  ﬁrst  frozen
HV model.
nimal trials: ﬁrst promising results
ith  the  help  of  my  collaborator  Helene  Eltchaninoff,  ani-
al  experiments  on  the  sheep  model  started  in  September
000 at  the  Centre  d’experimentation  et  de  recherche
ppliquée (CERA;  Institute  Montsouris,  Paris).  Through  the
rachiocephalic trunk,  the  ﬁrst  successful  implantation  of
 THV  within  the  native  aortic  valve  was  achieved,  with
xcellent results  and  no  complications.  After  this  case,  we
ad the  inkling  that  it  was  the  start  of  an  important  story.
he presentation  of  this  case  at  various  meetings  aroused
emorable and  encouraging  enthusiasm  from  the  medical
ommunity! More  than  100  implantations  at  different  car-
iac sites  were  subsequently  performed  by  us.  Soon,  with
xperience, we  switched  to  bovine  pericardium  for  the  valve
rosthesis.  We  learned  a  lot  from  this  experiment,  with
ase after  case  contributing  to  substantial  improvements  in
he THV  and  in  the  delivery  systems  and  implantation  tech-
iques. We  also  conceived  an  original  model  for  the  chronic
valuation of  the  THV  in  the  systemic  circulation  [14],  which
emonstrated the  persistence  of  excellent  valve  function
nd the  integrity  of  the  THV  on  pathological  examination  at
 months.
irst-in-human implantation
pril  16th,  2002  —– the  date  of  the  ﬁrst-in-human  implan-
ation [15]  —– will  remain  a  memorable  day.  A  57-year-old
atient with  severe  AS  presented  in  cardiogenic  shock  with
ajor left  ventricular  dysfunction  (the  ejection  fraction  was
2%!) and  multiple  comorbidities  contraindicating  AVR.  After
ailed  emergent  BAV,  TAVI  appeared  to  be  the  last-resort
ption for  this  young  patient.  The  indication  was  particularly
e
c
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hallenging  in  this  critically  ill  patient  who  also  had  subacute
eg ischaemia  related  to  an  aortofemoral  bypass  occlu-
ion and  severe  contralateral  atherosclerosis  preventing  the
se of  the  transfemoral  retrograde  access.  All  information
oncerning this  never-used  therapeutic  option  was  given
o the  patient’s  relatives  and  the  patient  himself,  all  of
hom gave  their  consent  with  no  hesitation.  The  proce-
ure was  performed  the  following  day  with  my  collaborators
elene Eltchaninoff  and  Christophe  Tron,  using  the  ante-
rade transseptal  approach.  This  unplanned  approach  added
tress to  the  procedure,  although  we  had  experience  of
sing it  in  a  few  BAV  cases  with  no  arterial  access.  Actually,
ach step  of  the  procedure  was  amazingly  straightforward.
tabilizing the  THV  across  the  native  valve  was  quite  chal-
enging, but  after  some  time,  we  succeeded  and  rapidly
eployed it.  Haemodynamic  and  echocardiographic  results
ere incredibly  improved,  with  no  transvalvular  gradient
nd a  return  of  blood  pressure  to  normal,  allowing  discon-
inuation of  vasopressors.  There  was  no  impairment  of  the
oronary ostia  or  the  mitral  valve,  no  atrioventricular  block
nd only  mild  paravalvular  aortic  regurgitation.  On  transoe-
ophageal echocardiography,  valve  function  was  excellent.
o words  can  express  the  emotion  felt  by  the  whole  team.
e were  witnessing  a  true  resurrection.  Despite  an  episode
f pulmonary  embolism,  the  patient  continued  his  clinical
ecovery. Unfortunately,  the  perfusion  of  his  leg  continued
o worsen  and  after  an  above-knee  amputation  that  never
ealed properly,  the  patient  passed  away  4  months  after
AVI.
This ﬁrst  case  conﬁrmed  the  feasibility  of  implanting  a
HV in  a  human  on  the  beating  heart  using  transcatheter
echniques, with  perfect  subcoronary  position  and  no  inter-
erence  with  the  surrounding  structures,  thus  translating  our
ostmortem observation  of  1993.
The  international  reaction  to  this  spectacular  case  deﬁed
magination. The  deafening  silence  during  the  video  pre-
entation of  this  case  in  meetings  was  testament  to  the
egree of  emotion  and  stupefaction  of  the  medical  com-
unity. Clearly,  this  ﬁrst-in-man  case  can  be  considered  a
reakthrough in  the  history  of  interventional  cardiology.
irst Rouen series
fter  three  additional  cases  we  obtained  permission  from
he French  Administration  to  start  a  feasibility  trial  at  our
entre. The  programme  was  approved,  but  restricted  to
ompassionate use.  We  recruited  16  patients  into  a  ﬁrst
tudy (I-REVIVE  trial),  where  the  THV,  further  modiﬁed
y the  use  of  an  equine  pericardial  valve,  was  implanted
sing either  an  antegrade  or  a  retrograde  (n  =  7)  approach
16]; 20  additional  patients  were  recruited  into  in  a  second
eries (RECAST  trial),  where  the  access  was  antegrade  in
ll patients  [17].  Each  case  was  special  and  each  implanta-
ion was  incredible.  These  studies  conﬁrmed  the  feasibility
f TAVI  (80%  procedural  success)  and  the  lasting  haemody-
amic and  functional  improvement  after  implantation.  As
xpected, several  of  these  critically  ill  patients  died  of  their
omorbidities within  weeks  or  months  but,  amazingly,  some
urvived beyond  2  to  5  years  and  even  as  long  as  6.5  years  in
ur most  striking  case,  without  any  prosthesis  dysfunction.
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The  incidence  of  25%  moderate-to-severe  paravalvular
aortic regurgitation  was  related  to  the  unique  23-mm  THV
size available.  The  extension  of  the  protocol  to  other  centres
in Europe  and  the  USA  clearly  demonstrated  the  limita-
tion of  this  unusual  transseptal  route  in  less  experienced
hands. Further  expansion  of  TAVI  clearly  required  technical
improvements, simpliﬁcation  of  the  procedure,  alternative
approaches and  a  larger  valve  size.
Edwards Lifesciences: transcatheter aortic
valve  implantation (TAVI) takes ﬂight
With  the  acquisition  of  PVT  by  Edwards  Lifesciences  (Irvine,
CA, USA)  in  January  2004,  TAVI  entered  a  new  era.  Rapid
improvements were  made  to  the  valve  prosthesis  and  deli-
very systems  and  new  approaches  were  developed  for  THV
implantation.
The Edwards  SAPIEN  valve  (initially  the  Cribier-Edwards
valve) consisted  of  a  tri-leaﬂet  bovine  pericardium  valve,
pretreated to  decrease  calciﬁcation,  mounted  in  a  balloon-
expandable stainless  steel  stent.  The  prosthesis  became
available in  two  sizes:  23  and  26  mm.  The  delivery  system
incorporated a  deﬂectable  Retroﬂex  catheter,  brilliantly
conceived for  the  transfemoral  retrograde  approach  and
initially evaluated  by  Webb  et  al.  in  Vancouver  [18].  Simul-
taneously, the  minimally  invasive  transapical  approach  was
developed using  another  delivery  system  (Ascendra),  evalu-
ated by  Walther  et  al.  in  Leipzig  [19].  Unfortunately,  French
investigators could  only  access  these  technologies  after  1
year of  delay,  in  the  setting  of  several  European  feasibility
studies (REVIVE,  PARTNER  and  TRAVERSE  trials).  The  satis-
factory results  of  these  trials,  despite  speciﬁc  complications
with the  two  approaches,  led  to  a  growing  acknowledgement
and considerable  expansion  of  TAVI  worldwide.
Concurrently,  another  device  had  been  progressing  since
2004: the  CoreValve  [20]  (now  produced  commercially  by
Medtronic, Irvine,  CA,  USA)  had  an  autoexpandable  nitinol
stent containing  a  porcine  pericardial  valve,  which  allowed
its transfemoral  insertion  through  smaller  sheaths  sizes  (21F
then 18F)  than  the  22F  and  24F  sizes  required  for  the
Edwards devices  —– a  major  appealing  feature  for  a  number
of teams.  As  an  alternative  to  the  transfemoral  approach,
the subclavian  access  was  proposed  with  the  CoreValve.  The
Conformité Européenne  (CE)  mark  was  obtained  for  both
models of  valve  in  2007.
Setting up transcatheter aortic valve
implantation  (TAVI) in the therapeutic
armamentarium  for calciﬁc aortic stenosis
Thereafter,  acceptance  and  expansion  of  TAVI  was  ama-
zing. In  line  with  the  statements  by  the  European  Associ-
ation of  Cardiothoracic  Surgery  (EACTS)  and  the  European
Society of  Cardiology  (ESC)  [21],  several  hundred  patients
were included  in  postmarketing  registries  conducted  with
the two  models  of  valves  and  using  the  different  approaches,
including the  European  SOURCE  registry  with  the  Edwards
SAPIEN valve  [22].  These  registries  contributed  to  better
appraisal of  patient  screening,  improvements  in  technical
T
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odalities  and  better  prevention  and  management  of
omplications. The  immediate  and  long-term  results  kept
mproving with  experience  and  advancing  technologies;  the
rocedural success  rate  progressively  reached  more  than
5%. Excellent  haemodynamic  results,  comparing  favourably
ith the  results  of  surgical  AVR,  lasting  functional  improve-
ent and  improved  survival  were  consistently  observed.
omplications were  also  shown  to  decrease  with  experience,
eaching an  acceptable  level  in  this  high-risk  population,  and
ere similar  for  both  valve  models,  with  the  exception  of
 more  frequent  incidence  of  conduction  disturbances  with
he CoreValve.  Overall,  the  results  of  TAVI  became  more  pre-
ictable. A  mortality  rate  of  6  to  10%  at  1  month  and  a  1-year
urvival rate  of  80%  could  be  quoted  after  transfemoral  TAVI
n  the  SOURCE  registry  [22].
The  results  of  the  pivotal  PARTNER  randomized  study
ith the  Edwards  SAPIEN  prosthesis,  conducted  from  2009
n 26  centres  in  USA  and  including  1056  high-surgical-
isk patients,  were  eagerly  expected  [23,24].  Patients
ere divided  into  two  cohorts:  operable  patients  randomly
ssigned to  TAVI  (transfemoral  or  transapical)  or  AVR  and
on-operable patients  randomly  assigned  to  transfemoral
AVI or  medical  treatment.  Brieﬂy,  the  results  conﬁrmed
hat in  non-operable  patients  TAVI  is  highly  superior  to
tandard therapy,  markedly  reducing  the  rate  of  all-cause
ortality and  repeat  hospitalization  at  1 year  (with  an
bsolute increase  in  survival  of  20%),  whereas  in  high-
urgical-risk patients,  TAVI  is  not  inferior  to  surgical  AVR
n terms  of  all-cause  mortality  at  1  year.  In view  of  these
esults, TAVI  was  approved  by  the  FDA  in  November  2011
or non-surgical  candidates;  approval  for  high-risk-patients
hould hopefully  occur  soon.  Subsequent  to  FDA  approval,
bout 400  centres  should  open  for  TAVI  within  a  couple  of
ears in  USA  and  active  training  has  already  been  initiated
n new  centres.
Innovations in  valve  and  delivery  systems  are  ongoing.
ince 2010,  the  new  SAPIEN-XT  valve,  which  includes  a
obalt chromium  highly  resistant  frame,  a  new  valve  and
eaﬂet design  and  an  additional  valve  size  (29  mm),  has  been
vailable in  Europe.  This  comes  with  new  delivery  systems
the NovaFlex  for  the  transfemoral  approach  is  compatible
ith smaller  sheath  sizes  [18F  and  19F],  which  increases
he rate  of  transfemoral  access  to  80%  of  patients)  and  an
mproved delivery  system  for  the  transapical  approach.  Sev-
ral  other  advances  are  already  in  use  or  under  evaluation,
ncluding a  smaller  valve  size  (20  mm)  and  other  valve
odels by  Edwards.  The  new  AcuTrack  delivery  system
or CoreValve  implantation  should  also  improve  further  the
ccuracy of  valve  placement.  There  is  no  doubt  that  these
apidly evolving  technologies  will  markedly  contribute  to  the
xpansion of  TAVI  in  the  near  future.
To  date,  it  is  estimated  that  50,000  patients  in  more  than
00 European  centres  have  beneﬁted  from  TAVI  with  the  two
odels of  prosthesis  and  the  technique  continues  to  evolve.
his obviously  supports  the  clear-cut  clinical  need  for  this
echnology.he situation in France
t  is  unfortunate  that  administrative  constraints  prevented
rance, which  had  been  pioneering  TAVI,  from  participating
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n  the  development  of  the  technology,  with  each  technolo-
ical advance  being  ﬁrst  evaluated  in  Canada  or  Germany.
his led  to  slow  growth  of  the  procedure  in  our  country
ntil 2010.  Thanks  to  many  colleagues  and  partners  from
he industry,  reimbursement  of  TAVI  was  obtained  from
ur national  insurance  (Sécurité  Sociale)  in  January  2010,
ith the  subsequent  approval  of  33  TAVI  centres  throughout
he country.  Subsequently,  the  number  of  TAVI  procedures
xploded in  France,  reaching  nearly  2300  patients  for  the
ear 2011  —– a  number  still  more  than  twofold  lower  than  in
ermany. Nevertheless,  among  a  number  of  national  regis-
ries, the  French  experience,  as  reﬂected  in  the  FRANCE
25] and  FRANCE  2  registries,  which  included  3500  patients,
ffers the  largest  prospective  and  exhaustive  overview  of
he state  of  the  art  in  real  life  with  the  two  models  of  valve.
n increased  number  of  TAVI  centres  in  France  is  pending.
uture prospects
t  has  already  been  observed  that  lower-risk  patients  in
urope are  receiving  TAVI  [25]  and  that  clinical  outcomes  are
etter [26].  Extension  of  TAVI  to  intermediate-risk  patients
ill be  evaluated  in  European  studies  (the  SURTAVI  trial)
s well  as  in  the  PARTNER  2  study  in  the  USA.  Exten-
ion of  the  indication  to  younger  and  low-risk  patients,
ot to  say  to  all  AS  patients,  would  certainly  require
urther technical  improvements  and  better  prevention  of
evere complications,  particularly  vascular,  haemorrhagic
nd cerebral  complications,  as  well  as  conduction  abnor-
alities and  paravalvular  leak,  and  greater  knowledge
f the  long-term  durability  of  valves  and  platform  sys-
ems.
Reductions in  sheath  size  and  new  approaches  (transaor-
ic) are  expected  to  further  decrease  haemorrhagic  and
ascular complications,  which  occur  in  2  to  30%  of  patients
ndergoing TAVI  [27,28]  and  have  a  negative  impact  on  the
hort-term clinical  follow-up  [22,29].
Neurological  event  rates,  reported  to  range  from  1.7  to
% [22,25,30—32],  remain  an  issue.  The  cause  of  stroke  is
ultifactorial but  most  periprocedural  and  postprocedural
trokes may  be  of  embolic  origin,  as  shown  by  post-TAVI
agnetic resonance  imaging:  new  cerebral  lesions  have
een reported  in  58  to  91%  of  patients  undergoing  TAVI
33], with  no  assessment  of  corresponding  neurocognitive
onsequences. Approaches  to  embolic  prevention  include
orous membranes  covering  the  carotid  ostia  and  carotid
lters, which  deserve  further  investigation,  and  a  search
or optimal  periprocedural  and  postprocedural  antiplatelet
trategies.
Complete heart  block  is  frequently  reported  after  TAVI.
t is  apparent  that  the  9  to  36%  rate  of  new  pacemaker
mplantation  with  the  CoreValve  is  much  higher  than  the  3
o 12%  rate  reported  with  the  Edwards  device  [25,34,35].
HVs implanted  lower  into  the  left  ventricular  outﬂow
ract against  the  interventricular  septum  may  increase
he risk  of  heart  block  [30].  Better  THV  positioning  with
mproved delivery  systems  might  decrease  the  incidence  of
his complication.
Moderate to  severe  (>  grade  2)  paravalvular  aortic  regur-
itation is  infrequent,  observed  in  less  than  10%  of  cases
nd is  typically  due  to  bulky  calciﬁcation,  technical  sizing
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r  positioning  errors  [30,36].  Better  determination  of  aortic
alve anatomy  and  calciﬁcation,  optimal  valve  size  and  posi-
ioning using  advanced  imaging  techniques,  as  well  as  new
rosthesis design,  might  decrease  the  rate  of  paravalvular
ortic insufﬁciency  in  the  future.
Importantly,  it  is  unknown  whether  the  favourable
idterm durability  of  the  currently  used  THV  will  be  con-
rmed in  the  long  term.  Although  clinical  follow-up  remains
imited, structural  THV  failure  has  only  been  reported  anec-
otally. One  report  documents  normal  valve  function  3  to
 years  after  implantation  of  the  SAPIEN  precursor,  the
ribier-Edwards valve  [37],  and  the  longest  follow-up  is
.5 years  in  our  series.  Again,  structural  failure  was  not
bserved. The  similar  manufacturing  of  the  Edwards  THV  and
urgical bioprosthesis  and  the  circumferential  frame  open-
ng of  the  THV,  avoiding  inappropriate  leaﬂet  overlapping,
re promising,  but  this  has  to  be  addressed  in  longer-term
ollow-up. Whether  THV  implantation  will  offer  similarly
ood results  in  congenital  bicuspid  valves,  which  occur  more
requently in  younger  patients,  remains  uncertain.
Other  indications  for  TAVI  have  emerged  recently,  with
he treatment  of  degenerated  bioprosthesis.  The  ﬁrst  results
re highly  encouraging  [38],  but  formal  evaluation  of  valve-
n-valve therapy  is  planned  in  the  upcoming  SAPIEN-XT
ARTNER 2  and  CoreValve  REDO  studies.
Finally,  a  number  of  next-generation  THVs  are  in  early
linical evaluation.  The  aim  was  to  incorporate  features  to
educe delivery  catheter  proﬁle,  facilitate  accurate  posi-
ioning, reduce  paravalvular  leaks  and  allow  for  retrieval,
nd they  are  generally  self-expanding.  Although  these
odels of  THV  might  represent  the  future  of  TAVI,  mini-
al information  is  available  to  date  on  efﬁcacy,  procedural
utcomes and  durability.
onclusions
he  development  of  TAVI  has  been  a  20-year  odyssey  from
oncept to  real  world,  but  it  has  been  a  fascinating  adven-
ure and  the  procedure  is  here  to  stay.  TAVI  already  plays  a
ajor role  in  the  management  of  patients  with  AS  and  can
e considered  the  standard  of  care  in  non-operable  patients,
s well  as  a  valuable  alternative  for  patients  at  high  surgical
isk. An  optimal  multidisciplinary  collaboration  for  patient
creening and  procedures  and  formally  trained  experienced
hysicians are  the  keys  to  success.  Each  indication  for  TAVI
s a  matter  of  clinical  judgment  and  it  should  be  reserved
or the  subset  of  patients  in  whom  a  good  outcome  is  likely.
One  can  proudly  observe  the  excellence  and  unequalled
artnership generated  by  TAVI.  Cardiologists,  cardiac  sur-
eons, anaesthesiologists,  imaging  specialists,  geriatricians,
urses and  technicians  have  learned  to  work  together
owards a  unique  goal:  making  TAVI  possible,  safe  and  suc-
essful with  optimal  patient  outcome.
Within  5  years,  an  extension  of  indications  to  lower-risk
atients can  be  expected,  as  well  as  an  explosion  of  centres
nd investigators  worldwide.  Simpliﬁed  and  safer  techniques
ill soon  be  available,  with  rapid  and  consistent  technolog-
cal improvement.  Although  work  still  needs  to  be  done  to
mprove techniques  and  outcomes  further,  the  future  of  TAVI
ooks  bright.
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